Q1 2022

Filed May 17, 2022 · 10-Q · 47 days after period end · 0001410578-22-001755

Q1 2022 · 10-Q

Revenue—

Net Income

-$25.99K

no prior Q1 2021 on file

EPS Diluted

$0.00

no prior Q1 2021 on file

Operating Cash Flow-$113,035—

Same quarter

no prior Q1 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2022 · filed May 17, 2022 · 47 d after period end

Tevogen Inc. · CIK 1860871 · Engraved from SEC EDGAR